FDA Inspection
Eosera, Inc.Eosera, Inc. – FDA Inspection, Mar 20, 2026
Record Details
This FDA Inspection record concerns Eosera, Inc., with an inspection on March 20, 2026, issued by the Dallas District Office, covering human drugs.
View Company Profile
ID · 6a760a07-14f0-4bff-8ac2-037a6b847e72
Inspection Facts
- Inspection number
- 1308346
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
FDA Citations
10- 21 CFR 211.100(a)Absence of Written Procedures
- 21 CFR 211.160(b)Scientifically sound laboratory controls
- 21 CFR 211.182Specific information required in individual logs
- 21 CFR 211.192Investigations of discrepancies, failures
- 21 CFR 211.22(d)Procedures not in writing, fully followed
- 21 CFR 211.63Equipment Design, Size and Location
- 21 CFR 211.67(b)Written procedures not established/followed
- 21 CFR 211.68(a)Calibration/Inspection/Checking not done
- 21 CFR 211.84(d)(2)Testing Each Component for Conformity with Specs
- 21 CFR 211.84(e)Rejecting When Specifications Not Met
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Eosera, Inc.
3| Date | Classification | Office | Project area |
|---|---|---|---|
| April 28, 2025 | Not classified | Dallas District Office | Drug Quality Assurance |
| March 1, 2022 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| January 17, 2020 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Eosera, Inc.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.